JP2013166765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013166765A5 JP2013166765A5 JP2013080823A JP2013080823A JP2013166765A5 JP 2013166765 A5 JP2013166765 A5 JP 2013166765A5 JP 2013080823 A JP2013080823 A JP 2013080823A JP 2013080823 A JP2013080823 A JP 2013080823A JP 2013166765 A5 JP2013166765 A5 JP 2013166765A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- natalizumab
- subject
- medicament according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 42
- 201000006417 multiple sclerosis Diseases 0.000 claims description 38
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 208000024908 graft versus host disease Diseases 0.000 claims description 37
- 150000003431 steroids Chemical class 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 32
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 27
- 208000006673 asthma Diseases 0.000 claims description 21
- 229960005027 natalizumab Drugs 0.000 claims description 20
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 17
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 9
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 208000023002 juvenile spondyloarthropathy Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 description 21
- 102000018358 immunoglobulin Human genes 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000036487 Arthropathies Diseases 0.000 description 6
- 208000012659 Joint disease Diseases 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 229920002877 acrylic styrene acrylonitrile Polymers 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55812004P | 2004-04-01 | 2004-04-01 | |
| US60/558,120 | 2004-04-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506536A Division JP2007531761A (ja) | 2004-04-01 | 2005-03-30 | ステロイド節約剤およびそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013166765A JP2013166765A (ja) | 2013-08-29 |
| JP2013166765A5 true JP2013166765A5 (enExample) | 2015-03-19 |
Family
ID=34972924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506536A Pending JP2007531761A (ja) | 2004-04-01 | 2005-03-30 | ステロイド節約剤およびそれを使用する方法 |
| JP2013080823A Pending JP2013166765A (ja) | 2004-04-01 | 2013-04-08 | ステロイド節約剤およびそれを使用する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506536A Pending JP2007531761A (ja) | 2004-04-01 | 2005-03-30 | ステロイド節約剤およびそれを使用する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050260193A1 (enExample) |
| EP (1) | EP1734997B1 (enExample) |
| JP (2) | JP2007531761A (enExample) |
| AU (1) | AU2005232571A1 (enExample) |
| CA (1) | CA2561364C (enExample) |
| DK (1) | DK1734997T3 (enExample) |
| ES (1) | ES2554754T3 (enExample) |
| HU (1) | HUE026236T2 (enExample) |
| IL (1) | IL178302A (enExample) |
| MY (1) | MY162179A (enExample) |
| NO (1) | NO20064979L (enExample) |
| NZ (1) | NZ594476A (enExample) |
| PL (1) | PL1734997T3 (enExample) |
| PT (1) | PT1734997E (enExample) |
| SI (1) | SI1734997T1 (enExample) |
| TW (1) | TWI462744B (enExample) |
| WO (1) | WO2005099776A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1592440A4 (en) | 2003-02-10 | 2007-07-11 | Elan Pharm Inc | IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| AU2012202575B2 (en) * | 2004-11-19 | 2014-11-20 | Biogen Ma Inc. | Treatment for Multiple Sclerosis |
| EP1827491A4 (en) * | 2004-11-19 | 2010-07-14 | Biogen Idec Inc | TREATMENT OF MULTIPLE SCLEROSIS |
| AU2006348180A1 (en) * | 2006-09-13 | 2008-03-20 | Warner Chilcott Company, Llc | Methods of treatment for ulcerative colitis |
| JP2008120722A (ja) * | 2006-11-10 | 2008-05-29 | Benesis Corp | 生物由来製品の偽薬 |
| WO2008125903A2 (en) * | 2006-12-12 | 2008-10-23 | Chaim Sheba Medical Center | Method of inhibiting an undesired immune response |
| CN102770151B (zh) | 2009-08-03 | 2018-07-31 | 因卡伯实验室有限责任公司 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
| US8562589B2 (en) | 2009-12-24 | 2013-10-22 | Rani Therapeutics, Llc | Swallowable drug delivery device and method of delivery |
| EP2543388A4 (en) * | 2010-03-04 | 2013-11-27 | Dainippon Sumitomo Pharma Co | MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE |
| ES2805873T3 (es) | 2010-04-16 | 2021-02-15 | Biogen Ma Inc | Anticuerpos anti-VLA-4 |
| JP2013528622A (ja) * | 2010-06-04 | 2013-07-11 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 炎症性障害の処置 |
| LT3722808T (lt) | 2010-10-25 | 2024-12-27 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumo, koreliuojančio su skirtumais svcam ir/arba smadcam lygiuose, nustatymo būdai |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US9284367B2 (en) * | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| AU2012250872B2 (en) | 2011-05-02 | 2017-07-13 | Millennium Pharmaceuticals, Inc. | Formulation for anti-alpha4beta7 antibody |
| ES2667854T3 (es) * | 2011-07-07 | 2018-05-14 | Holy Stone Healthcare Co., Ltd. | Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación |
| WO2013078375A2 (en) * | 2011-11-23 | 2013-05-30 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| US11097005B2 (en) | 2014-12-15 | 2021-08-24 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity |
| WO2016138538A2 (en) * | 2015-02-27 | 2016-09-01 | The General Hospital Corporation | Therapeutic use of integrin-binding antibodies |
| CN112867394B9 (zh) | 2018-06-04 | 2024-12-06 | 马萨诸塞州渤健公司 | 具有降低的效应功能的抗vla-4抗体 |
| WO2019241580A1 (en) * | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition |
| US20230181714A1 (en) * | 2020-05-27 | 2023-06-15 | Vanderbilt University | Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5224539A (en) | 1991-06-14 | 1993-07-06 | Coen Company, Inc. | Cooling system for air heaters and the like |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| AU2505599A (en) * | 1998-02-10 | 1999-08-30 | Cangene Corporation | Method for the prevention and treatment of a type i hypersensitivity disorder |
| CN100369903C (zh) * | 2000-06-30 | 2008-02-20 | 大日本住友制药株式会社 | 五元环化合物 |
| US6794506B2 (en) * | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| JP2004536786A (ja) * | 2001-03-02 | 2004-12-09 | メディミューン，インコーポレイテッド | インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法 |
| AU2002256507A1 (en) * | 2001-05-09 | 2002-11-18 | Novartis Ag | Methods for selective immunomodulation using pimecrolimus |
| US20030008844A1 (en) * | 2001-05-17 | 2003-01-09 | Keryx Biopharmaceuticals, Inc. | Use of sulodexide for the treatment of inflammatory bowel disease |
| DE60228108D1 (de) * | 2001-10-19 | 2008-09-18 | Chru Tours | Methoden und kompositionen zur bewertung von antikörper behandlungen |
| US6878518B2 (en) * | 2002-01-22 | 2005-04-12 | The Trustees Of The University Of Pennsylvania | Methods for determining steroid responsiveness |
| SI1485127T1 (sl) * | 2002-02-25 | 2011-09-30 | Elan Pharm Inc | Dajanje aktivne snovi za zdravljenje vnetja |
| AU2004207536B2 (en) | 2003-01-24 | 2010-05-20 | Elan Pharmaceuticals Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
-
2005
- 2005-03-29 MY MYPI20051380A patent/MY162179A/en unknown
- 2005-03-30 CA CA2561364A patent/CA2561364C/en not_active Expired - Lifetime
- 2005-03-30 EP EP05768245.2A patent/EP1734997B1/en not_active Revoked
- 2005-03-30 ES ES05768245.2T patent/ES2554754T3/es not_active Expired - Lifetime
- 2005-03-30 HU HUE05768245A patent/HUE026236T2/en unknown
- 2005-03-30 SI SI200532025T patent/SI1734997T1/sl unknown
- 2005-03-30 WO PCT/US2005/010848 patent/WO2005099776A2/en not_active Ceased
- 2005-03-30 JP JP2007506536A patent/JP2007531761A/ja active Pending
- 2005-03-30 NZ NZ594476A patent/NZ594476A/xx not_active IP Right Cessation
- 2005-03-30 AU AU2005232571A patent/AU2005232571A1/en not_active Abandoned
- 2005-03-30 PL PL05768245T patent/PL1734997T3/pl unknown
- 2005-03-30 DK DK05768245.2T patent/DK1734997T3/en active
- 2005-03-30 PT PT57682452T patent/PT1734997E/pt unknown
- 2005-03-31 TW TW094110385A patent/TWI462744B/zh not_active IP Right Cessation
- 2005-04-01 US US11/096,074 patent/US20050260193A1/en not_active Abandoned
-
2006
- 2006-09-26 IL IL178302A patent/IL178302A/en active IP Right Grant
- 2006-10-31 NO NO20064979A patent/NO20064979L/no not_active Application Discontinuation
-
2013
- 2013-04-08 JP JP2013080823A patent/JP2013166765A/ja active Pending
-
2014
- 2014-07-28 US US14/444,862 patent/US20150056205A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013166765A5 (enExample) | ||
| JP6654967B2 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| Ding et al. | Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study | |
| JP7564347B2 (ja) | 多発性硬化症を治療するためのｌｏｕ０６４ | |
| CN116261463A (zh) | 治疗痛风的方法 | |
| Santomasso | Anticancer drugs and the nervous system | |
| Shukla et al. | Novel non-biologic targets for inflammatory bowel disease | |
| Puig et al. | Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up | |
| Zhang et al. | BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy | |
| Seni et al. | Advancements in ulcerative colitis management: a critical assessment of etrasimod therapy | |
| Lolis et al. | Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies | |
| JP5954916B1 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| Bazzichi et al. | Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial | |
| US20240270842A1 (en) | Use of an anti-cd19 antibody to treat myasthenia gravis | |
| JP2025514978A (ja) | 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用 | |
| CN106659738B (zh) | 阿尔茨海默病(ad)的治疗和预防 | |
| AU2022230300A1 (en) | Treatment and/or reduction of occurrence of migraine | |
| AU2018361975A1 (en) | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists | |
| CANSEVER et al. | Successful Rapid Desensitization of Two Teenagers with Rituximab Hypersensitivity. | |
| Cianci et al. | Subcutaneous immunoglobulin in infantile chronic inflammatory demyelinating polyneuropathy: A case report | |
| Nobile-Orazio et al. | Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders | |
| Boucher et al. | Emerging Drugs for Amyotrophic Lateral Sclerosis | |
| EP4652199A1 (en) | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy | |
| Sorbera et al. | hu1124 | |
| US10576101B2 (en) | Roneparstat combined therapy of multiple myeloma |